Related references
Note: Only part of the references are listed.Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents
X. Luo et al.
NANOSCALE (2017)
A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma
Tuomas Tammela et al.
NATURE (2017)
Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi et al.
NATURE REVIEWS CANCER (2017)
The intrinsically disordered tails of PTEN and PTEN-L have distinct roles in regulating substrate specificity and membrane activity
Glenn R. Masson et al.
BIOCHEMICAL JOURNAL (2016)
Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment
Joao Conde et al.
NATURE MATERIALS (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo
Bin Li et al.
NANO LETTERS (2015)
Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs
Kevin J. Kauffman et al.
NANO LETTERS (2015)
The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase
Thomas R. Cox et al.
NATURE (2015)
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Jonathan E. Zuckerman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment
Xi Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Biomaterials for mRNA delivery
Mohammad Ariful Islam et al.
BIOMATERIALS SCIENCE (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
Nicolas Bertrand et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Targeting Tumor Suppressor Networks for Cancer Therapeutics
Xuning Emily Guo et al.
CURRENT DRUG TARGETS (2014)
First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors
Beate Schultheis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Single-cell mRNA transfection studies: Delivery, kinetics and statistics by numbers
Carolin Leonhardt et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
Structure-based programming of lymph-node targeting in molecular vaccines
Haipeng Liu et al.
NATURE (2014)
POINTS OF SIGNIFICANCE Nonparametric tests
Martin Krzywinski et al.
NATURE METHODS (2014)
Non-viral vectors for gene-based therapy
Hao Yin et al.
NATURE REVIEWS GENETICS (2014)
Multi-Level Kinetic Model of mRNA Delivery via Transfection of Lipoplexes
Thomas S. Ligon et al.
PLOS ONE (2014)
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA
Jonathan E. Zuckerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Kathryn A. Whitehead et al.
NATURE COMMUNICATIONS (2014)
Systemic Delivery of Modified mRNA Encoding Herpes Simplex Virus 1 Thymidine Kinase for Targeted Cancer Gene Therapy
Yuhua Wang et al.
MOLECULAR THERAPY (2013)
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug
Xiaoyang Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival
Benjamin D. Hopkins et al.
SCIENCE (2013)
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Josep Tabernero et al.
CANCER DISCOVERY (2013)
Recent Advances in Nonviral Vectors for Gene Delivery
Xia Guo et al.
ACCOUNTS OF CHEMICAL RESEARCH (2012)
The role of osmotic polysorbitol-based transporter in RNAi silencing via caveolae-mediated endocytosis and COX-2 expression
Mohammad Ariful Islam et al.
BIOMATERIALS (2012)
Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors
Dirk Strumberg et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
The functions and regulation of the PTEN tumour suppressor
Min Sup Song et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Accelerated gene transfer through a polysorbitol-based transporter mechanism
Mohammad Ariful Islam et al.
BIOMATERIALS (2011)
PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
Tamara L. Lotan et al.
CLINICAL CANCER RESEARCH (2011)
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Michael S. D. Kormann et al.
NATURE BIOTECHNOLOGY (2011)
Bone metastasis in prostate cancer: emerging therapeutic strategies
Justin Sturge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Katrin Knop et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA
Luigi Warren et al.
CELL STEM CELL (2010)
Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells
S. Zou et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2010)
mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers
Joanna Rejman et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
Current prospects for mRNA gene delivery
Ayako Yamamoto et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2009)
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
Kanishka Sircar et al.
JOURNAL OF PATHOLOGY (2009)
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression
Bo Han et al.
MODERN PATHOLOGY (2009)
Knocking down barriers: advances in siRNA delivery
Kathryn A. Whitehead et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
Eric Campeau et al.
PLOS ONE (2009)
Is PTEN loss associated with clinical outcome measures in human prostate cancer?
P. McCall et al.
BRITISH JOURNAL OF CANCER (2008)
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Frank Alexis et al.
MOLECULAR PHARMACEUTICS (2008)
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akin Akinc et al.
NATURE BIOTECHNOLOGY (2008)
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
M. Yoshimoto et al.
BRITISH JOURNAL OF CANCER (2007)
Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis
Martine Schmitz et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias
Maisa Yoshimoto et al.
CANCER GENETICS AND CYTOGENETICS (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion
PCMS Verhagen et al.
JOURNAL OF PATHOLOGY (2006)
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis
K Hamada et al.
GENES & DEVELOPMENT (2005)
A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids
ML Read et al.
NUCLEIC ACIDS RESEARCH (2005)
Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease
SA Backman et al.
NATURE GENETICS (2001)
PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression
H Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells
T Bettinger et al.
NUCLEIC ACIDS RESEARCH (2001)
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse
A Di Cristofano et al.
NATURE GENETICS (2001)
Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases
J Liliental et al.
CURRENT BIOLOGY (2000)